1. Oncological long-term outcomes of laparoscopic versus open gastrectomy for cT3-4 gastric cancer at surgical staging: a propensity-score matched cohort study.
- Author
-
Manuel, Arrieta G., Kinoshita, Takahiro, Amini, Neda, Akimoto, Eigo, Yura, Masahiro, Yoshida, Mitsumasa, Habu, Takumi, Nagata, Hiromi, Komatsu, Masaru, Sano, Junichi, and Terajima, Daiki
- Subjects
- *
GASTRECTOMY , *STOMACH tumors , *BODY mass index , *LAPAROSCOPIC surgery , *PROBABILITY theory , *SEX distribution , *TREATMENT effectiveness , *TERTIARY care , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *SURGICAL blood loss , *CHI-squared test , *AGE distribution , *SURGICAL complications , *LONGITUDINAL method , *ODDS ratio , *KAPLAN-Meier estimator , *MEDICAL records , *ACQUISITION of data , *TUMOR classification , *COMPARATIVE studies , *SURVIVAL analysis (Biometry) , *DATA analysis software , *CONFIDENCE intervals , *PROGRESSION-free survival , *TIME , *OVERALL survival ,DIGESTIVE organ surgery - Abstract
Background: The oncological efficacy of laparoscopic surgery for advanced gastric cancer (AGC) has been evaluated by several randomized trials. However, the inclusion of earlier-stage disease was a limitation in previous studies. Methods: Patients with cT3-4 gastric cancer, determined by surgical staging to minimize migration of earlier stages, treated at a tertiary cancer center from 2009 to 2018 were included. Based on the surgical approach, the patients were divided into two groups: the laparoscopic gastrectomy (LG) and the open gastrectomy (OG) and matched for age, sex, macroscopic appearance (type 4 or non-type 4), body mass index, estimated tumor size, clinical stage T3'T4, clinical N stage, pathologic T stage (T3 or T4), and type of surgery (total or distal gastrectomy). Results: 588 patients (221 LG, 367 OG) were included in the analysis. After 1:1 propensity-score matching, 386 patients (193 LG, 193 OG) were assigned for analysis. In the LG group, operation time was longer with lower blood loss. The incidence of postoperative complications (≥ grade III) did not differ significantly between the groups (OG: 8.3%, vs. LG: 9.3%). Overall survival (OS) was longer in the LG group (5-year OS: 79.3 vs. 73% HR 0.66, 95% CI 0.44–0.99, P = 0.0497). Relapse-free survival (RFS) did not show a statistical difference (5-year RFS: 69.5 vs. 68.7 HR 0.88, 95% CI 0.62–1.26, P = 0.487). Subgroup analysis for OS also demonstrated equivalent outcomes. Conclusion: LG demonstrates comparable safety and efficacy to OG for advanced gastric cancer at surgical staging, with similar rates of severe complications and long-term oncological outcomes. Further research is needed to validate these findings, particularly for total gastrectomy and for patients from Western populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF